Welcome, Guest. Please login or register.
August 09, 2020, 01:05:41 am

Login with username, password and session length

  • Total Posts: 703
  • Total Topics: 252
  • Online Today: 11
  • Online Ever: 334
  • (July 01, 2012, 10:57:46 pm)
Users Online
Users: 0
Guests: 7
Total: 7


Welcome to the Real Health Forums. Share your stories and thoughts on the many health challenges facing us today. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Real Health Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: New Class of Heart Disease Drugs  (Read 3900 times)

0 Members and 1 Guest are viewing this topic.

Offline iana5252

  • Administrator
  • Member
  • Posts: 65
New Class of Heart Disease Drugs
« on: June 23, 2015, 04:49:44 pm »
Patients and doctors across the country are getting excited about a class of drugs that promise to drop patients' cholesterol levels to unprecedented lows. What's more, the pharmaceutical company that developed the first of these drugs, alirocumab, just received support for its approval from the U.S. Food and Drug Administration (FDA) advisory committee.

Findings from studies of drugs in this class showed that some patients' LDL cholesterol levels dropped as low as those found in infants. The drugs are called PCSK9 inhibitors. They work by helping the body produce more LDL cholesterol receptors on liver cells that pull cholesterol out of the blood like a sponge and keep blood vessels clear of potential clogs.

Researchers said they were inspired to develop the drugs by the fact that some people are born with a genetic mutation that makes them naturally deficient in the PCSK9 enzyme. People deficient in this enzyme have naturally low LDL cholesterol levels and heart disease risk throughout their lives (with no adverse health effects reported).

« Last Edit: June 23, 2015, 04:53:06 pm by iana5252 »


© 2020 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.